Francesco Galimi has been appointed senior vice president and chief medical officer of Adicet Bio. Galimi comes to the Menlo Park, CA-based cancer drug developer from Amgen (NASDAQ: [[ticker:AMGN]]), where he was global program general manager of early development. His experience also includes positions at Onyx Pharmaceuticals and the Genomics Institute of the Novartis Research Foundation. Preclinical-stage Adicet is developing allogeneic, or “off-the-shelf,” cancer cell therapies.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
